Long-term efficacy of

Long-term efficacy of

To determine the efficacy of Y [DOTA , D-Phe , Tyr ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Median PF...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2016-08, Vol.12 (16), p.1877-1885
Hauptverfasser: Rogowski, Wojciech, Wachu a, Ewa, Lewczuk, Anna, Buscombe, John R, Seklecka, Nina, Sankowski, Artur, wik a, Jaros aw B
Format: Artikel
Sprache:eng
Schlagworte:
clinical and radiological response
GEP-NET
Y-DOTATATE therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1885
container_issue 16
container_start_page 1877
container_title Future oncology (London, England)
container_volume 12
creator Rogowski, Wojciech
Wachu a, Ewa
Lewczuk, Anna
Buscombe, John R
Seklecka, Nina
Sankowski, Artur
wik a, Jaros aw B
description To determine the efficacy of Y [DOTA , D-Phe , Tyr ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.
doi_str_mv 10.2217/fon-2016-0031
format Article
fullrecord <record><control><sourceid>futurescience</sourceid><recordid>TN_cdi_futurescience_futuremedicine_10_2217_fon_2016_0031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_fon_2016_0031</sourcerecordid><originalsourceid>FETCH-futurescience_futuremedicine_10_2217_fon_2016_00313</originalsourceid><addsrcrecordid>eNqlzr0KwjAUBeCLKFh_xu59gei9TWzsLIqDo3so6Y1EbApNO_j2tugbOJ1zhgMfQEq4y3PSe9cGkSMVAlHSDBLSSomjRJqPXelSFEWplrCK8YmotDxgAumtDQ_Rc9dk7Jy3lX1nrdvAwlWvyNtfrqG8nO-nq3BDP3Qcredg2XxXw7W3PrAhNJPDjA4zOczkkP98P246Pow</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term efficacy of</title><source>PubMed Central</source><creator>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; wik a, Jaros aw B</creator><creatorcontrib>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; wik a, Jaros aw B</creatorcontrib><description>To determine the efficacy of Y [DOTA , D-Phe , Tyr ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2016-0031</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>clinical and radiological response ; GEP-NET ; Y-DOTATATE therapy</subject><ispartof>Future oncology (London, England), 2016-08, Vol.12 (16), p.1877-1885</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachu a, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Buscombe, John R</creatorcontrib><creatorcontrib>Seklecka, Nina</creatorcontrib><creatorcontrib>Sankowski, Artur</creatorcontrib><creatorcontrib>wik a, Jaros aw B</creatorcontrib><title>Long-term efficacy of</title><title>Future oncology (London, England)</title><description>To determine the efficacy of Y [DOTA , D-Phe , Tyr ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</description><subject>clinical and radiological response</subject><subject>GEP-NET</subject><subject>Y-DOTATATE therapy</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqlzr0KwjAUBeCLKFh_xu59gei9TWzsLIqDo3so6Y1EbApNO_j2tugbOJ1zhgMfQEq4y3PSe9cGkSMVAlHSDBLSSomjRJqPXelSFEWplrCK8YmotDxgAumtDQ_Rc9dk7Jy3lX1nrdvAwlWvyNtfrqG8nO-nq3BDP3Qcredg2XxXw7W3PrAhNJPDjA4zOczkkP98P246Pow</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Rogowski, Wojciech</creator><creator>Wachu a, Ewa</creator><creator>Lewczuk, Anna</creator><creator>Buscombe, John R</creator><creator>Seklecka, Nina</creator><creator>Sankowski, Artur</creator><creator>wik a, Jaros aw B</creator><general>Future Medicine Ltd</general><scope/></search><sort><creationdate>20160801</creationdate><title>Long-term efficacy of</title><author>Rogowski, Wojciech ; Wachu a, Ewa ; Lewczuk, Anna ; Buscombe, John R ; Seklecka, Nina ; Sankowski, Artur ; wik a, Jaros aw B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-futurescience_futuremedicine_10_2217_fon_2016_00313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>clinical and radiological response</topic><topic>GEP-NET</topic><topic>Y-DOTATATE therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rogowski, Wojciech</creatorcontrib><creatorcontrib>Wachu a, Ewa</creatorcontrib><creatorcontrib>Lewczuk, Anna</creatorcontrib><creatorcontrib>Buscombe, John R</creatorcontrib><creatorcontrib>Seklecka, Nina</creatorcontrib><creatorcontrib>Sankowski, Artur</creatorcontrib><creatorcontrib>wik a, Jaros aw B</creatorcontrib><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rogowski, Wojciech</au><au>Wachu a, Ewa</au><au>Lewczuk, Anna</au><au>Buscombe, John R</au><au>Seklecka, Nina</au><au>Sankowski, Artur</au><au>wik a, Jaros aw B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term efficacy of</atitle><jtitle>Future oncology (London, England)</jtitle><date>2016-08-01</date><risdate>2016</risdate><volume>12</volume><issue>16</issue><spage>1877</spage><epage>1885</epage><pages>1877-1885</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To determine the efficacy of Y [DOTA , D-Phe , Tyr ]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response. Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender. Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/fon-2016-0031</doi></addata></record>
fulltext fulltext
identifier ISSN: 1479-6694
ispartof Future oncology (London, England), 2016-08, Vol.12 (16), p.1877-1885
issn 1479-6694
1744-8301
language eng
recordid cdi_futurescience_futuremedicine_10_2217_fon_2016_0031
source PubMed Central
subjects clinical and radiological response
GEP-NET
Y-DOTATATE therapy
title Long-term efficacy of
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A55%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20efficacy%20of&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Rogowski,%20Wojciech&rft.date=2016-08-01&rft.volume=12&rft.issue=16&rft.spage=1877&rft.epage=1885&rft.pages=1877-1885&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2016-0031&rft_dat=%3Cfuturescience%3E10_2217_fon_2016_0031%3C/futurescience%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true